As part of the agreement, PDS Biotech received $25 million at the close and can receive an additional $10 million if needed. The loan will be paid back over 48 months, according to an Aug. 24 PDS Biotech news release provided to Becker’s.
Proceeds from the loan agreement will be used to support the clinical development of drug candidates.
